Frequently Asked Questions about Bristol-Myers Squibb Company (BMY)

Name: Bristol-Myers Squibb Company (BMY) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Bristol-Myers Squibb Company (BMY) do?

Accepted Answer

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunom...

Question 2

Is Bristol-Myers Squibb Company (BMY) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of BMY reveals an Altman Z-Score of 2.28 and a Piotroski F-Score of 8/9. These metrics, combined with its 5-year revenue trend ($48.19B most recent), help investors decide if BMY fits their risk profile.

Question 3

What is the current P/E ratio for BMY?

Accepted Answer

As of the latest trading session, Bristol-Myers Squibb Company (BMY) has a trailing P/E ratio of 17.17.

Question 4

Who is the CEO of Bristol-Myers Squibb Company?

Accepted Answer

The current Chief Executive Officer of Bristol-Myers Squibb Company is Christopher S. Boerner.

Question 5

What was BMY's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Bristol-Myers Squibb Company reported annual revenues of $48.19B (2025), $48.30B (2024), $45.01B (2023), $46.16B (2022), $46.38B (2021) respectively.

Question 6

Does BMY pay a dividend?

Accepted Answer

Bristol-Myers Squibb Company currently pays a dividend to its shareholders, with a trailing dividend yield of 4.21%.

Question 7

How much debt and cash flow does BMY have?

Accepted Answer

In its latest reporting period, Bristol-Myers Squibb Company generated $12.85B in Free Cash Flow against a total debt load of $47.14B.

Question 8

What is the Price-to-Book (P/B) ratio of Bristol-Myers Squibb Company?

Accepted Answer

The Price-to-Book (P/B) ratio for Bristol-Myers Squibb Company (BMY) is currently 6.56.

Question 9

What is the Price-to-Sales (P/S) ratio of BMY?

Accepted Answer

Based on trailing twelve-month data, Bristol-Myers Squibb Company (BMY) trades at a Price-to-Sales (P/S) ratio of 2.51.

Question 10

What is Bristol-Myers Squibb Company's Return on Equity (ROE)?

Accepted Answer

Bristol-Myers Squibb Company (BMY) has a Return on Equity (ROE) of 39.27%, representing its profitability relative to shareholder equity.

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2025-12	14.2B	553M	-1.3B	12.8B	12.3B
2024-12	15.2B	507M	-1.2B	13.9B	13.4B
2023-12	13.9B	518M	-1.2B	12.7B	12.1B
2022-12	13.1B	457M	-1.1B	11.9B	11.5B
2021-12	16.2B	583M	-973M	15.2B	14.7B

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2025-12	14.2B	553M	-1.3B	12.8B	12.3B
2024-12	15.2B	507M	-1.2B	13.9B	13.4B
2023-12	13.9B	518M	-1.2B	12.7B	12.1B
2022-12	13.1B	457M	-1.1B	11.9B	11.5B
2021-12	16.2B	583M	-973M	15.2B	14.7B